Denali Therapeutics (NASDAQ:DNLI) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up [Yahoo! Finance]
Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review [Yahoo! Finance]
Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Denali Therapeutics (NASDAQ:DNLI) was given a new $25.00 price target on by analysts at UBS Group AG.